EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs

Aida N Kawuma iD, Francis Williams Ojara iD, Allan Buzibye iD, Barbara Castelnuovo iD, Jovia C Tabwenda iD, Jacqueline Kyeyune iD, Christine Turyahabwe iD, Simon Peter Asiimwe iD, Johnson Magoola iD, Lubbe Wiesner iD, Ritah Nakijoba iD, Catriona Waitt iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Aida N Kawuma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. Hauptthemen laut MEDLINE: Rifampin, Lactation, Milk, Human, Breast Feeding. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacokinetic studies are important for understanding drug disposition in the human body. However, pregnant and lactating women are often excluded from primary pharmacokinetic studies and as such there is often limited dosing information regarding drug use in pregnant and/or lactating women. The objectives of this interim analysis were to define the transfer of rifampicin to a breastfed infant and to determine the area under the concentration–time curve of rifampicin in maternal plasma, breastmilk and infant plasma. Performing this interim analysis enabled us to substantiate whether prior assumptions we made on several study design issues including patient sample size and pharmacokinetic sampling times held and whether we needed to amend our protocol or not. We enrolled lactating mothers on treatment for tuberculosis with their breastfeeding infants (below 12 months of age), performed intensive pharmacokinetic sampling (0–24 h post‐dose) on plasma samples from both the mother, infant(s) and breastmilk samples from the mother on two separate occasions (once during the initiation phase and another during the continuation phase of tuberculosis treatment). The initial study design, including sampling times, was informed by a stochastic simulation and estimation exercise, with very limited prior breastmilk data. An interim analysis after recruiting 6 mother–infant pairs ascertained that our initial assumptions were ideal for achieving our study objectives and no amendments to the sampling times were necessary. Initial data from 6 mother–infant pairs show that rifampicin penetrates breastmilk with an approximate milk‐to‐plasma ratio of 0.169 and 0.189 on two separate visits. However, it was undetectable in most infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinLactationMilk, HumanBreast FeedingHumansFemaleInfantAdultAntibiotics, AntitubercularInfant, NewbornArea Under CurveTuberculosisPregnancyYoung Adult

Substanzen

RifampinAntibiotics, Antitubercular

Autor:innen und Institutionen

  • Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Department of Pharmacology and Therapeutics, Gulu University, Gulu, Uganda.
  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.

ORCID-Profile: Aida N Kawuma, Francis Williams Ojara, Allan Buzibye, Barbara Castelnuovo, Jovia C Tabwenda, Jacqueline Kyeyune, Christine Turyahabwe, Simon Peter Asiimwe, Johnson Magoola, Lubbe Wiesner, Ritah Nakijoba, Catriona Waitt

Förderung

  • The Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • NIAID NIH HHS
  • NIH HHS
  • NIMH NIH HHS
  • Wellcome Trust
  • FIC NIH HHS
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Kawuma, A. N., Ojara, F. W., Buzibye, A., Castelnuovo, B., Tabwenda, J. C., Kyeyune, J., Turyahabwe, C., Asiimwe, S. P., Magoola, J., Wiesner, L., Nakijoba, R., & Waitt, C. (2024). Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13247

Vancouver

Kawuma AN, Ojara FW, Buzibye A, Castelnuovo B, Tabwenda JC, Kyeyune J, et al. Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13247

BibTeX
@article{Kawuma2024,
  author = {Kawuma, Aida N and Ojara, Francis Williams and Buzibye, Allan and Castelnuovo, Barbara and Tabwenda, Jovia C and Kyeyune, Jacqueline and Turyahabwe, Christine and Asiimwe, Simon Peter and Magoola, Johnson and Wiesner, Lubbe and Nakijoba, Ritah and Waitt, Catriona},
  title = {Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13247}
}
Kostenlos starten →